The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies. [electronic resource]
Producer: 20130626Description: 189-94 p. digitalISSN:- 0392-856X
- Aged
- Antibodies, Monoclonal, Murine-Derived -- therapeutic use
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- diagnosis
- Case-Control Studies
- Female
- Genotype
- Humans
- Linear Models
- Male
- Middle Aged
- Pharmacogenetics
- Phenotype
- Polymorphism, Genetic
- Receptors, IgG -- genetics
- Rituximab
- Severity of Illness Index
- Time Factors
- Treatment Outcome
- Tumor Necrosis Factor-alpha -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.